Skip to content

Diagnostic Value of PUMCH (Peking Union Medical College Hospital) Allergen Extracts for Skin Prick Test in vivo

Study on PUMCH Allergenic Extracts from Pollen used for Skin Prick Test

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014899
Enrollment
Unknown
Registered
2018-02-13
Start date
2015-08-10
Completion date
Unknown
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis, Allergic ocular conjunctivitis, allergic asthma

Interventions

Gold Standard:sIgE levels were determined by using the immunoCAP assay (Phadia, Uppsala, Sweden). sIgE =0.35 KUA/L were judged as positive and sIgE<0.35 were judged as negative.
Prick&#32
Test&#32
results&#32
wered&#32
by&#32
Wheal&#32
(MWD),&#32
the&#32
of&#32
long&#32

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 66 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged from 4 to 70 years male or female; (2) Diagnosed as allergic conjunctivitis, allergic rhinitis, allergic asthma, urticaria or dermitis; (3) Intradermal skin test or sIgE test must be completed before skin prick test; (4) Written informed consent was received.

Exclusion criteria

Exclusion criteria: (1) Subjects were pregnant or lactating women; (2) Subjects had taken antihistamines before the trail or withdrawal time in less than five half-lives; (3) Subjects were taking the systemic corticosteroids medicine; (4) Subjects had skin nick disease; (5) Subjects had negative result in Positive control test (a wheal=5mm) or positive result in negative control test in the skin prick test; (6) Subjects had skin infections,dermatitis,scar or other pathological changes; (7) Subjects had participated in other clinical trial in the recent 3 months; (8) Subjects had systemic diseases, such as hypertension or coronary heart disease (CHD); (9) Subjects were taking beta blockers, including topical treatment; (10) Subjects were in acute exacerbation, such as in the acute exacerbation of allergic asthma; (11) Subjects were Suffering from psoriasis; (12) In other conditions which the investigators considered unsuitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
sensibility, specificity, positive predictive values, negtive predictive values;Safety;

Countries

China

Contacts

Public ContactYin Jia

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

pumch_allergy@126.com+86 010-69156346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026